tbuckley/cabot-search huggingface dataset:
Age and gender influence the progression of AJCC Stage I/II melanoma
Authors: A. Mcelrath-Garza, L. Wanek, D. Morton
Journal: Journal of Clinical Oncology (2005)

7513 Background: Studies suggest that females diagnosed with melanoma have a better overall survival than males. Previous correlations between estrogen exposure and the development and progression of melanoma in female patients have shown conflicting results. Methods: Retrospective review identified 6988 patients treated for AJCC stage I/II melanoma by John Wayne Cancer Institute staff between 1971–2000. All patients underwent wide local excision with or without lymphadenectomy, within 6 months of diagnosis. A computer program randomly matched patients by age, T-stage, presence of ulceration, AJCC stage at diagnosis, and type of surgical treatment. Results: At a median follow-up of 98.4 months, the rate of melanoma-specific 10-year survival was 78.5% in 3043 females and 65.5% in 3945 males (p<0.0001). In the subgroup of 5288 patients matched by the above factors, 10-year survival rate was highest (80.5%) in females <50 years old at diagnosis, decreasing significantly (p<0.0001) in females >50 years (73.0%), males <50 years (70.0%), and males >50 years (65.1%). The 10-year survival rate was significantly (p<0.0001) higher for 1360 premenopausal women (81.0%) than 1235 postmenopausal females (73.4%) or 2764 males (67.9%). Increased parity was inversely related to 10-year survival: 80.6% for childless females versus 76.9% for those who had borne at least one child (p<0.0199). The use of hormone therapy by 1235 postmenopausal females did not affect survival of the postmenopausal subgroup (p=0.61). Conclusions: The risk of melanoma progression increases with age, probably because of the well known decrease in immune competence associated with aging. This is reflected by the improved gender-matched survival of our patients whose melanoma was diagnosed before age 50. The fact that older female patients survived longer than younger male patients suggests hormonal factors: estrogen might not be protective, whereas testosterone might promote melanoma progression. The complex relationship between age, gender and the influence of sex hormones merits further study. No significant financial relationships to disclose.
Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life
Authors: Jürgen Siekmann, Purtscher Martin, Oliver Zöchling, Robert Kellerer, Hanspeter Rottensteiner, Artur Mitterer, Marry Bossard, Gayle Phillips, Hartmut J. Ehrlich, Friedrich Scheiflinger, Peter L Turecek
Journal: Blood (2011)
P0177 : A simple operative criterion to assess patients with low grade of hepatic encephalopathy
Authors: F. Campagna, S. Montagnese, L Ridola, S. Schiff, D. Aprile, G. Testa, M. De Rui, M. Senzolo, S. Nardelli, I. Pentassuglio, C. Pasquale, A. Gatta, C. Merkel, O. Riggio, P. Amodio
Journal: Journal of Hepatology (2015)
MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Authors: Cayce Nawaf, Amanda Lu, James Rosoff, Jeffrey Weinreb, Peter Schulam, Peter Humphrey, Angelique Levi, Preston Sprenkle
Journal: Journal of Clinical Oncology (2016)

90 Background: Patients with an elevated PSA but negative prostate biopsy present a diagnostic and management dilemma. We evaluated the capability of multi-parametric (MP) MRI and MRI-USG Fusion prostate biopsy to detect clinically significant (CS) prostate cancer in men who have had a prior negative 12-core standard biopsy. Methods: Between 12/2012 and 06/2015, 374 men with an indication for prostate biopsy underwent pre-biopsy mpMRI followed by 12-core standard trans-rectal mapping biopsy (Mbx) and MRI-Ultrasound fusion targeted biopsy (Tbx) of lesions identified on mpMRI. The combination of Mbx and Tbx, when both occurred, constitutes a fusion biopsy (Fbx). Men who underwent both Mbx with or without Tbx using the Artemis/Pro-Fuse system with a previous biopsy but no diagnosis of prostate cancer were included. Patients without a lesion on MRI underwent Mbx only. Maximum Gleason scores (GS) was assigned on a per patient basis with Mbx GS available for all patients in the cohort and Tbx GS available only for patients with a lesion visible on MP-MRI. CS cancer was defined as GS ≥ 3+4. GS per patient was compared by chi-square and McNemar’s test. Results: 138 men (mean age = 64.0, mean psa = 11.6) met inclusion criteria. Fbx cancer detection rate in this population was 42%. 17 men (12%) were missed by Mbx but picked up on Tbx. Of these 17 men, 13 had Gleason ≥ 7.In comparison, 15 men were missed by Tbx, but only 2 were Gleason ≥ 7. Tbx had a higher rate of detection of CS cancer than Mbx, but this did not reach statistical significance (86% vs 68%, p = 0.09). MRI suspicion level correlated with the detection of CS cancer (p = 0.012). None of the 20 men with a negative MRI had GS ≥ 7 cancer detected on Mbx. The number of prior negative biopsies was not related to the likelihood of finding CS cancer on Fbx (p = 0.47). Conclusions: MRI suspicion score predicts detection of CS prostate cancer when paired with MRI-USG Fbx of the prostate, with a negative MRI correlating with no evidence of CS cancer on biopsy. MRI is a biomarker in this population that may, with more corroborative data, allow for men with a negative MRI to avoid repeat biopsies. [Table: see text]
Low CNS Relapse Incidence without Radiotherapy and Improvement of Outcome: Results of Subsequent EORTC-CLG 58881 and 58951 Trials in Pediatric T-Cell Acute Lymphoblastic Leukemia (ALL)
Authors: Barbara De Moerloose, Stefan Suciu, Alina Ferster, Françoise Mazingue, Nicolas Sirvent, Vitor Costa, Karima Yakouben, Patrick Lutz, Anne Uyttebroeck, Dominique Plantaz, Geneviève Plat, Frédéric Millot, Pierre Rohrlich, Maryline Poiree, Jutte Van der Werff Ten Bosch, Claire Hoyoux, Patrick Boutard, Hélène Cavé, Sandrine Girard, Francisco Bautista Sirvent, Yves Benoit, Yves Bertrand
Journal: Blood (2012)
The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST—Second annual summary.
Authors: M. Chacon, P. Reichardt, J. Gu, T. Nishida, C. H. Barrios, J. Blay, A. Reichardt, M. E. Blackstein, P. G. Casali, Y. Kang
Journal: Journal of Clinical Oncology (2010)

10092 Background: The GOLD reGISTry is a web-based, prospective, 5-year observational study capturing global/regional diagnosis and disease characteristics, treatment modalities, efficacy parameters, and outcome for patients (pts) with advanced GIST. Methods: Eligible pts had locally advanced, metastatic, or recurrent GIST diagnosed no more than 15 months prior to reGISTry entry. Detailed pt and center information are captured and summarized annually. Data are summarized as of July 2009. Results: The most common eligible diagnoses were recurrence with metastasis (35%) and initial diagnosis of metastatic GIST (30%). 1065 pts enrolled at 156 sites in 34 countries across 5 regions: Latin America (LA, 12%), EU West/Canada (EUW/C, 28%), EU East (EUE, 20%), Asia (A, 39%), and the Middle East (ME, 1%). Most sites are referral centers (89%) that see between 5 and 25 pts with localized (50%) and advanced disease (50%) annually. Mean age of pts was lower in A and LA (56 yrs) than in EUE (60 yrs) and EUW/C (62 yrs). Proportion of male pts was slightly higher in A (62%) than EUE (55%) and EUW/C (58%). Most pts (92.4%) had GIST as original diagnosis (7.6% non-GIST). Of 959 pts receiving any initial treatment for their eligible diagnosis, 801 pts got medication, most often imatinib (765 pts); 50.7% of pts remained on this initial medication at reGISTry enrollment. At enrollment, only 890/1065 pts had any medication prescribed. Of 309 surgeries performed for eligible diagnosis, 168 were complete resection of primary tumor. Primary tumors were mostly from small intestine (45%) and stomach (39%). Overall, CT scan was a routine method (100%) for GIST assessment; 18FDG-PET was less common. At eligible diagnosis, 107 pts (10%) had mutational analysis performed. To date, 105 discontinuations occurred, including 80 deaths (59 related to GIST progression). Follow-up data are available for 888 (83%) pts. Conclusions: Contrary to current guidelines for advanced and/or metastatic GIST, complete resection of the primary tumor is still performed and a number of pts are not receiving medication. Continued accrual of reGISTry data will assist in determining if closer adherence to the guidelines improves outcomes. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ARIAD, GlaxoSmithKline, Infinity, Merck, Novartis, Pfizer, PharmaMar, sanofi-aventis Novartis, Pfizer, PharmaMar, Tsumura & Co. Amgen, ARIAD, GlaxoSmithKline, Infinity, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer, PharmaMar, sanofi-aventis, Schering-Plough Pfizer, PharmaMar
Impact of cytogenetics on outcome of patients with MDS or secondary AML undergoing allogeneic HSCT from HLA-Identical siblings
Authors: Francesco Onida, Ronald Brand, Anja van Biezen, Renee M. Barge, Leo F. Verdonck, Jurgen Finke, Dietrich Beelen, Rodrigo Martino, Jose M. Fernandez-Ranada, Dietger Niederwieser, Nicolaus Kroeger, Theo de Witte
Journal: Blood (2006)
Integrating palliative care into care of patients with kidney cancer and melanoma.
Authors: Mary K. Buss, Susan DeSanto-Madeya, Jessica Lynch, Jessica A. Zerillo, David F. McDermott
Journal: Journal of Clinical Oncology (2014)

56 Background: Early palliative care (PC) has been shown to improve quality of life (QOL), enhance quality end-of-life (EOL) care, and reduce costs, yet many cancer centers lack resources to provide outpatient palliative care services. Data is needed to identify the optimal timing and most effective and efficient model for integrating PC into the care of cancer patients. In order to understand what components of PC have the greatest impact on patients, we examined the acceptability of early PC among patients with kidney cancer (RCC) and melanoma (M) and describe the content of PC visits. Methods: In July 2013, the outpatient PC team at Beth Israel Deaconess Medical Center, including physician (MD), social worker (SW) and chaplain (chap) were invited to see patients within a clinic that specializes in seeing patients with advanced RCC and M. All patients completed data on symptom burden using the Edmonton Symptom Assessment Scale, measures of QOL and degree of psycho-social and spiritual support. Referral to PC was based on these metrics and physician discretion. Results: Of the 21 patients seen by PC, 57% had RCC; 76% male; 86% White; 57% married. Mean age was 62 (range: 36-87). At the 1st PC visit: All had locally adv/metastatic disease; 48% were being treated with curative intent; 29% had not yet started treatment; 57% rated pain 0 on 0-10 scale (range: 0-9). First PC visit content: 76% psychosocial support (including building rapport); 67% symptom management; 33% included advance care planning (ACP) and decision-making support. Ninety-one percent were seen &gt;1 by PC; 19% seen by SW or chap; median PC visits: 3. Eighty-one percent completed health care proxy. Additional data on patient outcomes will be presented. Conclusions: Nearly half of patients seen by PC were being treated with curative intent, suggesting acceptability of early PC integration in patients with RCC and M. Symptom management and psychosocial support dominated the early PC visits.
Employee attitudes and smoking behavior at the City of Hope National Medical Center smoke-free campus
Authors: D. Lin, D. C. Stahl, D. Iklé, F. W. Grannis
Journal: Journal of Clinical Oncology (2004)

1025 Background: City of Hope National Medical Center (COH) in Duarte, CA has had a policy of allowing no smoking anywhere on the 100-acre campus since 1989. Because there is little published information on smoke-free campuses (SFC), we investigated the attitudes of employees at COH toward the SFC, and attempted to identify possible changes in the smoking behavior of employees. Methods: An anonymous survey was conducted to all 2787 campus employees using both web-based data entry and scannable paper forms. Employees with network access were contacted by email and those without computers were contacted in person. Respondents were asked questions regarding their attitudes toward the SFC as well as their smoking history and current smoking behavior. Study participants were stratified by self-reported smoking status. A smoker was defined as one who had smoked more than 100 cigarettes and had smoked within the past 30 days. An ex-smoker was defined as one who had smoked more than 100 cigarettes, but had not smoked within the past 30 days. A non-smoker was defined as one who had neither smoked 100 cigarettes nor smoked within the past 30 days. Results: There were 1356 responses (48.7%). 100 (7.4%) respondents were current smokers, 242 (17.8%) were ex-smokers, and 1014 (74.8%) were non-smokers. Smokers and ex-smokers smoked a mean of 2.4 cigarettes less (95% CI 1.8 to 3.1, p< .0001) on workdays than on days off with evidence of a small amount of compensatory smoking (one cigarette/day). 61.6% of smoking employees believed that the smoke-free campus reduced their cigarette consumption. 42.2% of smoking employees quit smoking while employed at COH between 1989–2002. 92.6% of respondents supported the COH SFC policy. High acceptance was consistent across gender, ethnicity, job type, and educational level. Conclusions: City of Hope's smoke-free campus policy is strongly supported by employees, and may decrease cigarette consumption and facilitate smoking cessation among smoking employees. The smoke free campus may represent an effective strategy in prevention of lung cancer and other diseases caused by tobacco products. No significant financial relationships to disclose.
Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.
Authors: Kyoung Ha Kim, Dong Hwan Dennis Kim, Jun Ho Jang, Kihyun Kim, Chul Won Jung, Jong-Ho Won, Joon Ho Moon, Sang Kyun Sohn, Yeo-Kyeoung Kim, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim, Jin Seok Kim, Yoo Hong Min, Dae-Young Kim, Je-Hwan Lee, Jung-Hee Lee, Kyoo-Hyung Lee, Inho Kim, Sung-Soo Yoon, Seonyang Park, Sang Min Lee, Young-Don Joo
Journal: Blood (2009)
酸化ストレスは赤血球変形能を障害する ベラパミルの保護的作用(Oxidant stress impairs erythrocyte deformability: Protective effect of verapamil)
Authors: Okamoto Kazuhiko, Maruyama Toru, Kaji Yoshikazu, Ito Hiroyuki, Uesaka Nobuhiro, Mawatari Shiro, Fujino Takehiko
Journal: Circulation (2002)
A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)
Authors: Francesco Passamonti, Vannucchi Alessandro, Caramazza Domenica, Rambaldi Alessandro, Morra Enrica, Kiladjian Jean Jacques, Rami S Komrokji, Margherita Maffioli, Jason Gotlib, Cervantes Francisco, Timothy Devos, Richard T. Silver, Paola Guglielmelli, Nicola Vianelli, Valerio De Stefano, Marco Ruggeri, Giorgina Specchia, Umberto Vitolo, Elisa Rumi, Barbara Mora, Tiziano Barbui, Lisa Pieri, Cristiana Pascutto, Mario Cazzola
Journal: Blood (2014)
¿ES POSIBLE MEJORAR LA CALIDAD DE LA COLONOSCOPIA CON UNA LLAMADA TELEFÓNICA?
Authors: L Cid Gomez, A Antunez Yañez, B Romero Mosquera, N Quintans Pinazas, D Martinez Ares, ML De Castro Parga, S Vazquez Rodriguez, P Estevez Boullosa, V Hernandez Ramirez, A Salgado Barreira, I Rodriguez Prada Jose
Journal: Endoscopy (2015)

Introducción: El grado de preparación de las colonoscopias es un determinante en la toma de decisiones con nuestros pacientes.
Intraplatform Reproducibility and Technical Precision of Gene Expression Profiling in Four Laboratories Investigating 112 Leukemia Samples: The DACH Study.
Authors: Alexander Kohlmann, Elisabeth Haschke-Becher, Barbara Wimmer, Ariana Huber-Wechselberger, Sandrine Meyer-Monard, Heike Huxol, Uwe Siegler, Michel Rossier, Thomas Matthes, Michela Rebsamen, Adeline Diemand, Alberto Chiappe, Sonja Rauhut, Wei-min Liu, Andrea Johnson, Lothar Wieczorek, Torsten Haferlach
Journal: Blood (2007)
Breast cancer during pregnancy—A prospective and retrospective European registry (GBG-20/BIG02–03)
Authors: S. Loibl, A. Ring, G. Von Minckwitz, M. Lenhard, F. Amant, C. Weiss, D. Augustin, V. Nekljudova, M. Kaufmann
Journal: Journal of Clinical Oncology (2008)

22143 Background: In the treatment of the pregnant breast cancer patients, the evidence upon which we base our decisions has been largely limited to case reports, case-control studies and retrospective cohorts. Therefore, the German Breast Group has launched a registry (GBG-29/BIG 02–03) for patients with breast cancer that has been diagnosed during pregnancy. Methods: Every pregnant breast cancer patient is eligible. The primary endpoint is the fetal outcome 4 weeks after delivery. Secondary endpoints are maternal outcome of pregnancy, stage and biological characteristics of breast cancer, breast cancer therapy (treatment, response to chemotherapy, type of surgery), sensitivity and specificity of diagnostic procedures, outcome of the newborn after 5 years, outcome of breast cancer 5 years after diagnosis. Results: From April 2003-December 2007, 122 patients have been prospectively (n=39) and retrospectively (n=83) registered. The median age is 33 years (range 24–43). T1–2: 71.7%; T3–4: 28.3%; N+ 66.6%; ductal invasive 83.8%, lobular 4.8%, inflammatory 4.8%, Grading 3: 69.5%, ER/PR neg 53.5%; Her-2 pos: 41.3%. At the time of diagnosis the median gestational age is 21 weeks; 21.6% of all patients have been diagnosed during the 1st, 43.3% during the 2nd and 35.1% during the 3rd trimester. From the patients who continued pregnancy, 33.3% received surgery only, 43.2% were treated by surgery and chemotherapy, 5.4% were treated only by chemotherapy and 2.7% had no treatment. Cytotoxic regimens used during pregnancy: EC/AC n=23, CMF n=11, FEC=7, taxane=11. The median time of delivery was 36 weeks (range 30–42), 54 newborns exposed to systemic therapy had alopecia (1), small for gestational age (1), 1 had trisomia 18 and died one week after birth, 1 had necrotic enterocolitis and died 3 weeks after birth. Fetal outcome in babies, who received intrauterine chemotherapy was not different from those who did not. Conclusions: Pregnant breast cancer patients can probably be treated as close as possible to standard recommendations in specialized multidisciplinary teams. The registry needs to be continued to get better data on long time follow-up. No significant financial relationships to disclose.
Milestones and Competency-Based Medical Education in Internal Medicine
Authors: Eric S. Holmboe, Stephanie Call, Robert D. Ficalora
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Prognostic relevance of gene-environment interactions in dilated cardiomyopathy patients: applying the MOGES classification
Authors: M. R. Mark Hazebroek, S Moors, R Dennert, A Van den Wijngaardt, I Krapels, M Hoos, J. J Merken, H Crijns, H. P Brunner-La Rocca, Stephane Heymans
Journal: European Journal of Heart Failure (2015)
PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
Authors: Cathy Eng, Elzbieta Nowara, Anna Swieboda-Sadlej, Niall C Tebbutt, Edith P Mitchell, Irina Davidenko, Elena Elez, Kelly S Oliner, Lisa Chen, Jing Huang, Ian McCaffery, Elwyn Loh, Dominic Smethurst, Eric Van Cutsem
Journal: Annals of Oncology (2011)
Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study.
Authors: Eric Jeffrey Sherman, Alan Loh Ho, Matthew G. Fury, Shrujal S. Baxi, Lara Dunn, Jennifer S Lee, Brynna Lane Lipson, David G. Pfister
Journal: Journal of Clinical Oncology (2015)

6069 Background: Everolimus is an oral inhibitor of the mammalian target of rapamycin complex 1 (mTORC1). Laboratory data suggests that mTORC1 activity is required for the growth promoting effects of the oncoproteins RET/PTC, RAS, and BRAF in rat thyroid PCCL3 cells. Sorafenib, an oral kinase inhibitor with activity against multiple targets, is FDA-approved for the treatment of radioactive iodine-refractory (RAIR) thyroid cancer. We conducted a clinical trial evaluating everolimus plus sorafenib for RAIR follicular cell derived thyroid cancers (DTC) and medullary thyroid cancers (MTC). Methods: This single institution study used a two-stage phase II design and was initiated on 9/21/10. Primary objective was response rate. Eligible patients (pts) had progressive, RAIR/fluorodeoxyglucose (18-F)-avid, recurrent/metastatic, non-anaplastic, thyroid cancer; RECIST measurable disease. Sorafenib was given at 400 mg orally twice a day and everolimus at 5 mg orally once daily. 41 pts were enrolled; 38 were eligible for the primary endpoint of response and 3 were evaluable for toxicity only at the data cutoff date of 1/21/15. 7 pts are still on study. Results: Of the 41 eligible pts, median age-61 years (35-79). 15 patients received prior VEGF-targeted systemic therapy. Grade 4-5 adverse events at least possibly related to drug: grade 4- hepatic enzyme increase (1 pt): grade 4- Hyperglycemia (1 pt): grade 4-Hypertriglyceridemia (1 pt). Histology and response data by partial response, confirmed and unconfirmed, (PR), stable disease (SD), progression of disease (POD), and days on study (DOS) are shown in the Table. Conclusions: The combination of sorafenib and everolimus demonstrates activity that rivals the best reported data, and surpasses that for sorafenib alone, in all evaluated thyroid cancer subgroups. A randomized study of sorafenib +/- everolimus is indicated in both pts with DTC and MTC. Clinical trial information: NCT01141309. Histology # PR SD POD Median DOS (range) Papillary 9 5 (56%) 3 (33%) 1 (11%) 484 (27-854+) Hurthle Cell 9 7 (78%) 2 (22%) 0 553 (55-1419+) Follicular 2 1 (50%) 1 (50%) 0 136 (80-192) Poorly Diff 8 4 (50%) 4 (50%) 0 262 (142-863+) MTC 10 4 (40%) 4 (40%) 2 (20%) 209 (31-1517+) DTC only 28 17 (61%) 10 (36%) 1 (4%) 430 (27-1419+) Total 38 21 (55%) 14 (37%) 3 (8%) 373 (27-1517+)